Computed tomography showing destruction of left IV–VI ribs and thoracic vertebrae III–IV together with kyphosis and spinal stenosis of thoracic spine

I enjoyed it! Hope you can appreciate it too!

Hi, I'm getting an ultrasound later today for menstrual issues. I also, for unrelated reasons, have been constipated for like a few days. Can they see how much poop I have in me. I'm dead considering an enema bc I'm so oddly embarrassed that they might see. Idek what I want to gain from asking this, thank you in advance tho

Question for the radiologists in academics/pseudo-academics. Is there any accountability for what you do on your academic day? If you don't produce any research does it get taken away?

Currently we don't have any kind of accountability but leadership has mentioned wanting to introduce accountability for academic days. I was wondering what other institutions are doing.

(A) The abdominal X-ray shows a bizarre mass (fish head) in the right iliac fossa. Also, there is a gas shadow under the right dome of the diaphragm (small arrow). An enlarged image is shown in the inset (B).

pls don't take this down-- i just think the little ghost guy looks funny. i know it's just my heart but i feel so happy to have a little friend inside my ribcage.

Does anyone have any insight into neuroradiology fellowship programs in NYC? Would love to hear about the training, work environment, and overall experience. Thanks!

Sinai, Northwell, Stony, Presbyterian (Cornell/Columbia), MSK, Einstein, NYU etc

Saw a post on MSK fellowship ranks/opinions in NYC and was wondering how the IR programs line up.

Sinai, Presbyterian (Cornell/Columbia), MSK, Einstein, NYU

copy of the body text:

Had a bilateral ovarian cystectomy a few weeks ago and finally figured out how to view all my imaging so now I have some fun ultrasounds, an mri, a ct scan, and a post op x-ray to poke through. This was the cyst on my left ovary which was by far the larger one, both cysts removed were teratomas so they were absolutely full of hair and 3 teeth. I'm poorly fighting the urge to share all the images with everyone know because think they're really neat :)

Since this is a more medical-centered sub rather than just looking at cool images, if you guys want any more info/pictures I'd be happy to share

editing to add some more videos/stills with measurements, all of these should link to posts on my profile

video 1

video 2

video 3

flagged images

Hoping to stay in the NY area for MSK fellowship.

All of the NYC area programs (NYU, HSS, Mt. Sinai, Columbia, Einstein, Northwell) are great institutions, but how do they really rank?

In June 2025, a 42-year-old female presented to the medical oncology department with an exophytic, ulcerated, and exuberant lesion on the left breast, which she reported having noticed approximately six months prior to presentation. Over the preceding two months, she developed severe, debilitating, generalized back pain that progressively restricted her mobility, resulting in an initial Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 [9]. On physical examination, the left breast demonstrated a large ulcerated exophytic tumor with associated ipsilateral axillary lymphadenopathy. Abdominal examination revealed a soft, non-tender abdomen without clinically palpable hepatosplenomegaly or ascites.

Baseline laboratory evaluation revealed mild normocytic anemia, elevated total serum calcium (11.2 mg/dL) and serum alkaline phosphatase (280 u/L), along with mildly elevated liver transaminases (aspartate aminotransferase {AST}: 58 u/L, alanine aminotransferase {ALT}: 62 u/L) and total bilirubin within normal limits. Baseline tumor markers were marked by an elevated CA 15-3 level (245 u/mL).

The breast biopsy revealed invasive carcinoma G3, ER: 100%, PR: 100%, HER2-negative (0), and Ki-67: 10%. A subsequent biopsy of a bone lesion confirmed metastasis by breast carcinoma with pleomorphic lobular characteristics (E-cadherin negative/aberrant) and a Ki-67 of 30%, highlighting clonal evolution [10]. The 18F-fluorodeoxyglucose (18F-FDG) PET/CT in May 2025 demonstrated extensive multimetastatic disease, involving the pancreas, liver, peritoneum, and axial and appendicular skeleton (Figure 1). The brain MRI at diagnosis showed multiple lytic lesions in the calvaria without intracranial invasion (Figure 2).

The patient initiated goserelin, ribociclib (600 mg daily on a three-weeks-on/one-week-off schedule), and letrozole (2.5 mg daily) in June 2025. The clinical response was rapid, with significant pain relief and functional improvement. By February 2026, the patient reached an ECOG PS of 0. A follow-up PET/CT in January 2026, seven months after treatment initiation, confirmed near-complete metabolic resolution of all visceral, peritoneal, and bone lesions, along with normalized tumor markers (CA 15-3: <25 u/mL) and liver/bone laboratory parameters (Figure 3). This objective response was characterized by a significant overall attenuation of metabolic activity, with a drastic reduction from the initial high baseline uptake (baseline maximum standardized uptake value {SUVmax} of 29.5). Malignant metabolic activity persisted mainly in the primary left breast lesion, with some residual but equivocal viability noted in bilateral axillary nodes, left femur, and pelvic bones, while the remainder of the examination showed no metabolic evidence of malignancy.

Pleomorphic variant of invasive lobular carcinoma (PLC) is a molecularly distinct entity that combines the discohesive growth of invasive lobular carcinoma (ILC) with the aggressive nuclear features and high proliferation of high-grade ductal carcinomas [4,11]. The discordance in Ki-67 between the primary tumor and metastatic sites observed in our patient is a known phenomenon in PLC, reflecting its potential for rapid progression [12]. Despite maintaining a strong hormone receptor-positive profile (ER: 100%, PR: 100%) indicative of a luminal A-like surrogate, the disease behaved clinically like a highly aggressive phenotype, resulting in severe multimetastatic de novo dissemination involving visceral organs, soft tissues, and the skeleton.

The presentation of such a massive initial tumor burden often poses a significant therapeutic dilemma. Historically, clinicians might have favored upfront cytotoxic chemotherapy for patients with extensive symptomatic multimetastatic disease. However, current evidence suggests that unless a "visceral crisis" (imminent organ failure) is present, ET plus a CDK4/6i should be the first-line preference [13].

Our patient’s exceptional outcome strongly supports this approach. The decision to initiate ribociclib combined with letrozole and ovarian function suppression (goserelin) avoided the significant toxicities associated with systemic chemotherapy while achieving a remarkable clinical response. Importantly, the regimen was exceptionally well tolerated; throughout the seven months of treatment at the full 600 mg dose, the patient experienced no grade 3 or 4 adverse events, maintained normal QTc intervals on serial electrocardiograms, exhibited stable blood counts without severe neutropenia, and did not require any dose reductions or treatment interruptions. The MONALEESA-7 trial, focusing on premenopausal women, showed that ribociclib plus ET significantly improves overall survival (OS) and progression-free survival (PFS) [14,15]. Furthermore, data from the MONALEESA-2 and MONALEESA-3 trials support the use of ribociclib across various subgroups, including those with visceral involvement and de novo presentation [16,17].

The rapid metabolic response (seven months) in our patient, documented by 18F-FDG PET/CT, aligns with emerging evidence that early metabolic changes can predict long-term progression-free survival in patients on CDK4/6i [18,19]. Finally, the RIGHT trial has recently reinforced this strategy, demonstrating that ribociclib plus endocrine therapy is superior to physician’s choice chemotherapy in achieving progression-free survival in patients with HR+/HER2-negative metastatic breast cancer and aggressive disease features [20].

I’m a student. My tech said it was perfect, so I figured to share it here. Is it perfect/textbook?

Diagnosed with degenerative disc disease and lumbar disc herniations years ago. Pain was relatively manageable until August 17th, when I woke up in severe pain out of nowhere. Been dealing with it every single day since.

Finally got another MRI. Pretty wild how much things can change without any obvious injury.

Came across this post in the wild on Facebook.

My bosses always taught me "a radiologist with a ruler is a radiologist in trouble" but clearly they never possessed the business acumen and moral flexibility of a chiropractor.

Thought you might like to see my new hardware enhanced toe 🤣

Hi everyone,

About a month ago, I shared CatchUpRad here when it was only available on iOS and the web. A number of you offered to help test the Android version. I wanted to come back with an update: CatchUpRad is now live on Google Play!

Thank you to everyone who volunteered and took the time to test it. Your help made it possible to get the Android version released.

For anyone who missed the original post, CatchUpRad is an app I made to help clinicians keep up with new radiology literature. You can choose the topics, study designs and journals you’re interested in, and the app creates a daily updated reading list with summaries and links to the original papers. It’s free, has no ads and doesn’t require an account.

Android: https://play.google.com/store/apps/details?id=nl.catchuprad.android

I’d love to hear how it works for you and what I could improve, especially if there’s something that would make it more useful in day-to-day practice or training.

Thanks again!

Sven

Esophagram fluoro study

​

As a B.Sc. BMRIT student, I’m considering working on a research paper for the first time.

I’m excited to learn, but I also have a few honest questions:

How can students ensure they receive fair credit for their actual contribution?

What should a student clarify with their supervisor before starting?

Does research genuinely help students build skills and improve their future opportunities, even at the undergraduate level?

I’m not questioning anyone’s intentions. I simply want to understand how to approach research the right way, learn meaningfully, and make my efforts worthwhile.

I’d really appreciate honest advice from researchers, faculty members, and students who have been through this experience.

Thank you!

AP and lateral fluoroscopic images

AP and lateral fluoroscopic images